|[January 20, 2014]
Research and Markets: 2013 Report on the Japanese HIV Drug Market - Forecasts to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/jxgbxw/pharmapoint_hiv)
has announced the addition of the "2013
Report on the Japanese HIV Drug Market - Forecasts to 2022"
report to their offering.
The treatment algorithm in HIV has characteristically involved multiple
drug regimens designed to tackle the virus on different levels. In the
recent past, simplified dosing regimens through the emergence of single
tablet regimens (STRs) or fixed dose combination (FDC) therapies have
become increasingly popular amongst physicians and patients alike by
increasing clinical efficacy thresholds and enabling patient compliance.
This can be explained by the low prevalence and incidene rates of HIV
Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has
claimed millions of lives since its emergence. However, the advent of
antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a
deadly disease to a manageable chronic condition for most infected
individuals. Antiretroviral treatment not only reduces the viral load
and reconstitutes immune function, but also decreases infection
incidence rates by limiting viral transmission.
The Japanese market is different from the other major markets in that
STR use has not yet been introduced. For example, Atripla, which is the
market leader in the US and Europe, is not currently licensed in Japan.
However, the first integrase-based STR, Gilead's Stribild, which was
approved by the FDA in August 2012, might be launched in Japan by the
end of 2013 or at the beginning of 2014. Japan Tobacco, through its
research alliance with Gilead, filed for market approval of elvitegravir
in December 2012 with the Japanese Ministry of Health, Labour and
Welfare. It is forecasted that ViiV will adopt a similar approach to
launch the novel INI-based inhibitor dolutegravir and 572-Trii into the
Key Topics Covered:
1 List of Tables and Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Opportunity and Unmet Need
7 Pipeline Assessment
8 Market Outlook
For more information visit http://www.researchandmarkets.com/research/jxgbxw/pharmapoint_hiv
[ InfoTech Spotlight's Homepage ]